On Oct 11, 2024, Pfizer's HYMPAVZI™ was FDA-approved for preventing bleeding episodes in hemophilia A and B, marking a major advancement in hemophilia care.
In the aftermath of Hurricanes Milton and Helene, we're offering guidance and online resources to help those with bleeding disorders access vital medical care and support.
The new webinar, which is free to attend, will speak to the ways in which a strong support network can help mitigate some of the inherent challenges associated with clinical trial participation.